Clinical OMICs empowers healthcare professionals to harness the application of molecular-based
technologies to transform patient care through a combination of news, contributed articles, and expert analysis.
Researchers have found that the TP53 gene has even greater anti-cancer activity than previously known.
The investment builds on a collaboration begun in 2015 to develop T2's diagnostic for Lyme disease that uses its T2MR mini MRI platform.
We will explore how liquid biopsies are shaping the diagnostic landscape and how it will impact physician decision making and patient care.
2015 was a phenomenal year full of new developments for the structures and mechanisms of CRISPR systems.